Louveau B, Resche-Rigon M, Lesimple T, Da Meda L, et al. Phase I-II open label multicenter study of palbociclib + vemurafenib in BRAFV600MUT metastatic melanoma patients: uncovering CHEK2 as a major response mechanism. Clin Cancer Res 2021 May 4. pii: 1078-0432.CCR-20-4050.
PMID: 33947696